Related Experiment Video
Updated: Jul 2, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and
Sanjiv Kandhari1, Abhishek De2, Krupa Shankar3
1Department of Dermatology, Dr. Kandhari's Skin and Dental Clinic, New Delhi, India.
Clinical, Cosmetic and Investigational Dermatology
|July 1, 2026
Summary
This expert recommendation offers practical guidance for using abrocitinib, a Janus kinase (JAK) inhibitor, to treat moderate-to-severe atopic dermatitis (AD) in India. It focuses on safe and effective real-world management, including dosing and monitoring for optimal patient outcomes.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition causing significant quality of life impairment.
- Conventional therapies for AD offer limited efficacy and tolerability.
- Janus kinase (JAK) inhibitors represent a targeted therapy advancement for AD management.
Purpose of the Study:
- To provide practical, experience-based recommendations for abrocitinib use in Indian patients with moderate-to-severe AD.
- To guide initiation, dosing, monitoring, and long-term management of abrocitinib in a real-world setting.
Main Methods:
- A multistep approach including literature review (Sept-Nov 2025), a nationwide survey of 36 dermatologists, and two expert panel meetings with 10 senior clinicians.
- Consensus-based recommendations for abrocitinib's clinical application in India.
Main Results:
- Abrocitinib is identified as a valuable systemic option for specific patient profiles, including those with pruritus-dominant disease, head/neck involvement, hand eczema, elderly patients with comorbidities, and those refractory to other treatments.
- Emphasis on comprehensive baseline risk assessment (hematologic, hepatic, renal, lipid, infectious, cardiovascular, thrombotic) and structured follow-up monitoring.
- Recommended induction dose of 200 mg daily, with 100 mg for select populations, alongside strategies for maintenance, tapering, and transitions.
Conclusions:
- Expert recommendations offer practical, real-world guidance for individualized, safe, and effective abrocitinib use in Indian patients with moderate-to-severe AD.
- Highlights the importance of structured monitoring and long-term treatment planning for optimal outcomes with abrocitinib.
Related Concept Videos
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...